Viromed Medical AG has successfully completed a capital increase first announced earlier today, placing 450,000 new registered no-par value shares at €4.50 per share, according to a release distributed via NEWMEDIAWIRE. The gross proceeds of approximately €2 million will be used to finance the company's working capital. The transaction matters because it strengthens the balance sheet of a small-cap medical technology firm that has been listed since October 2022 and is still in a growth phase, giving it the liquidity needed to support day-to-day operations and the rollout of its core product line.
Subject to registration of the implementation of the capital increase in the commercial register, Viromed's share capital will rise from €21,250,000 by €450,000 to €21,700,000. The increase was carried out by partially utilizing the Authorized Capital 2025 and with the exclusion of shareholders' subscription rights. That structure is significant for existing investors because it means the new shares were placed with selected parties rather than offered pro rata to all shareholders, diluting their stakes slightly while allowing the company to raise funds quickly and without a lengthy rights offering. The placement price of €4.50 per share provides a reference point for how the market values the company at this stage.
Viromed specializes in the development, manufacture and distribution of medical products, with its operating business focused on distributing innovative cold plasma technology for medical applications through its wholly owned subsidiary Viromed Medical GmbH. The company can draw on a broad customer base in the DACH region and beyond. It aims to further advance the use of cold plasma technology in medicine in the coming years and to realize the corresponding growth potential. The fresh capital is therefore directly tied to that strategy: without adequate working capital, scaling distribution and supporting customers in new markets would be difficult for a company of this size.
Additional details about the company and its business are available at www.viromed-medical-ag.de, and the full announcement can be viewed through the original release on www.newmediawire.com. For observers of the medical technology sector, the completion of this capital measure signals that Viromed has secured near-term funding and can continue pursuing its growth plans, while the exclusion of subscription rights and the modest dilution are points shareholders will weigh against the benefit of a stronger cash position.
